



Anti-L-DOPA monoclonal antibody (DMAB4563)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Using a conjugate L-DOPA-(Pc), antibody specificity was performed with an ELISA test by competition experiments with the following compounds : Compound Cross-reactivity ratio (a) L-DOPA-G-(Pc) 1 Dopamine-G-(Pc) 1/>50,000 Noradre
Immunogen	Synthetic L-DOPA conjugated to protein carrier (Pc)
Isotype	IgG1
Source/Host	Mouse
Species Reactivity	N/A
Conjugate	Unconjugated
Applications	Immunocytochemistry
Size	100 µl
Preservative	None
Storage	Store at -20°C. Avoid multiple freeze/thaw cycles.

BACKGROUND

Introduction	L Dopa is an intermediate in dopamine biosynthesis. Clinically, L Dopa is used in the management of Parkinson's disease. It is used as a prodrug to increased dopamine levels
---------------------	---

since it is able to cross the blood-brain barrier whereas dopamine itself cannot. Once L Dopa has entered the central nervous system(CNS), it is metabolised to dopamine by aromatic L amino acid decarboxylase. This also occurs in the peripheral tissues, causing adverse effects and decreasing the available dopamine to the CNS, so it is standard practice to administer a peripheral DOPA decarboxylase inhibitor and often a catechol-O-methyl transferase (COMT) inhibitor.

Keywords

3,4-dihydroxy L phenylalanine; L dihydroxyphenylalanine; Levodopa; BETA-(3,4-DIHYDROXYPHENYL)-L-ALANINE; HYDROXYTYROSINE; H-PHE(3,4-DI-HYDROXY)-OH; H-PHE(3,4-DI-OH)-OH; H-TYR(3-HYDROXY)-OH; L-BETA-(3,4-DIHYDROXYPHENYL)ALANINE; L-DOPA; L-DOPA, L-3-HYDROXYTYROSINE; LEVODOPA; L-3-(3,4-DIHYDROXYPHENYL)ALANINE; L-3,4-DIHYDROXYPHENYLALANINE; L-3-HYDROXYTYROSINE; L Dopa
